These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7563956)

  • 1. Effect of iron as a new type of phosphate binder in hemodialysis patients.
    Kuroda S; Komori M; Nagamatsu K; Ninomiya R; Maejima K; Hasegawa K; Samejima M; Kuroda M; Fujimori H; Kasai M
    Nihon Jinzo Gakkai Shi; 1995 Aug; 37(8):468-73. PubMed ID: 7563956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum ferritin in hemodialysis. I. Study in populations treated with iron or untreated].
    Marco Franco JE; Alarcón Zurita A; Morey Molina A; Pizá Buñola C; Bestard Palmer J; Mairata Bosch S; Galmés Llodra A; Dalmau Diana M
    Rev Clin Esp; 1981 Dec; 163(6):403-6. PubMed ID: 7342203
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
    Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
    Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 11. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease.
    Geisser P; Philipp E
    Clin Nephrol; 2010 Jul; 74(1):4-11. PubMed ID: 20557860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
    Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP;
    Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphate binders on iron basis: a new perspective?
    Hergesell O; Ritz E
    Kidney Int Suppl; 1999 Dec; 73():S42-5. PubMed ID: 10633463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ferrous citrate or ferrous sulfate use during predialysis may reduce serum phosphate level at dialysis initiation
.
    Koide S; Inaguma D; Koshi-Ito E; Takahashi K; Hayashi H; Tsuboi N; Hasegawa M; Yuzawa Y
    Clin Nephrol; 2019 Oct; 92(4):180-189. PubMed ID: 31347494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of aluminum hydroxide timing administration in relation to meals in controlling hyperphosphatemia in dialysis patients.
    Katopodis KP; Andrikos E; Pappas M; Siamopoulos KC
    Int J Artif Organs; 2005 Aug; 28(8):803-7. PubMed ID: 16211530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of SBR759, a new iron-based phosphate binder.
    Block GA; Brillhart SL; Persky MS; Amer A; Slade AJ
    Kidney Int; 2010 May; 77(10):897-903. PubMed ID: 20375984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
    Sinsakul M; Sika M; Koury M; Shapiro W; Greene T; Dwyer J; Smith M; Korbet S; Lewis J;
    Nephron Clin Pract; 2012; 121(1-2):c25-9. PubMed ID: 23075669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.
    Yamashita K; Mizuiri S; Nishizawa Y; Kenichiro S; Doi S; Masaki T
    Nephrology (Carlton); 2017 Dec; 22(12):947-953. PubMed ID: 27558654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.